Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the month of July 2022, with the report dated July 5, 2022. The filing serves to disclose a regulatory notification lodged with the Australian Securities Exchange (ASX) regarding the cessation of securities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate governance event rather than a financial performance statement.
Material Changes
The material change disclosed is the expiry of unlisted options under the company's employee incentive plan. Consequently, the company lodged a Notification of Cessation of Securities on Appendix 3H with the ASX on July 4, 2022.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly procedural, attaching the ASX notification as Exhibit 99.1.
Investor Verification Checklist
- Verify the specific number of options that expired under the employee incentive plan.
- Confirm the impact of this cessation on the company's total outstanding share count.
- Review the full text of the Appendix 3H notification (Exhibit 99.1) for details on the specific option holders or classes affected.